📊 Research Summary: The ImmunoSep trial demonstrates the potential for biomarker-guided immunotherapy in a subset of patients with sepsis. #CCRdownunder ja.ma/4pMi8wt
December 8, 2025 at 10:45 PM
📊 Research Summary: The ImmunoSep trial demonstrates the potential for biomarker-guided immunotherapy in a subset of patients with sepsis. #CCRdownunder ja.ma/4pMi8wt
Editorial by JAMA Senior Editor Derek Angus: The ImmunoSep RCT demonstrates the feasibility of biomarker-guided treatment, while highlighting ongoing challenges in immune classification and broader clinical application. #CCRdownunder ja.ma/3Kg3qz3
December 8, 2025 at 11:00 PM
Editorial by JAMA Senior Editor Derek Angus: The ImmunoSep RCT demonstrates the feasibility of biomarker-guided treatment, while highlighting ongoing challenges in immune classification and broader clinical application. #CCRdownunder ja.ma/3Kg3qz3
ImmunoSep uses a double-dummy design.
What is this? It is a design to maintain blinding when 2 treatments can't be made identical- all participants receive 2 treatments- one which is active and the other which is placebo #ccrdownunder
What is this? It is a design to maintain blinding when 2 treatments can't be made identical- all participants receive 2 treatments- one which is active and the other which is placebo #ccrdownunder
RCT: Among patients with #sepsis, a precision immunotherapy strategy targeting macrophage activation-like syndrome and sepsis-induced immunoparalysis improved organ dysfunction by day 9 compared to placebo.#CCRdownunder ja.ma/3MkSb95
December 8, 2025 at 10:46 PM
ImmunoSep uses a double-dummy design.
What is this? It is a design to maintain blinding when 2 treatments can't be made identical- all participants receive 2 treatments- one which is active and the other which is placebo #ccrdownunder
What is this? It is a design to maintain blinding when 2 treatments can't be made identical- all participants receive 2 treatments- one which is active and the other which is placebo #ccrdownunder
Just 4 weeks to CCR Down Under 2025!
Join us to hear the results of 8 major critical care trials - in person or virtually
➡️ ImmunoSep
➡️ iRehab
➡️ CLIP II
➡️ ACTiVE
➡️ ARISE AFRICA
➡️ RSI
➡️ VITaCCA
➡️ ECMO REHAB
https://criticalcarereviews.com/meetings/ccr-down-under-2025
Join us to hear the results of 8 major critical care trials - in person or virtually
➡️ ImmunoSep
➡️ iRehab
➡️ CLIP II
➡️ ACTiVE
➡️ ARISE AFRICA
➡️ RSI
➡️ VITaCCA
➡️ ECMO REHAB
https://criticalcarereviews.com/meetings/ccr-down-under-2025
November 11, 2025 at 10:10 PM
Just 4 weeks to CCR Down Under 2025!
Join us to hear the results of 8 major critical care trials - in person or virtually
➡️ ImmunoSep
➡️ iRehab
➡️ CLIP II
➡️ ACTiVE
➡️ ARISE AFRICA
➡️ RSI
➡️ VITaCCA
➡️ ECMO REHAB
https://criticalcarereviews.com/meetings/ccr-down-under-2025
Join us to hear the results of 8 major critical care trials - in person or virtually
➡️ ImmunoSep
➡️ iRehab
➡️ CLIP II
➡️ ACTiVE
➡️ ARISE AFRICA
➡️ RSI
➡️ VITaCCA
➡️ ECMO REHAB
https://criticalcarereviews.com/meetings/ccr-down-under-2025
Precision Immunotherapy to Improve Sepsis Outcomes - The ImmunoSep Randomized Clinical Trial
Evangelos J. Giamarellos-Bourboulis, et al.
JAMA, 2025
jamanetwork.com/journals/jam...
Evangelos J. Giamarellos-Bourboulis, et al.
JAMA, 2025
jamanetwork.com/journals/jam...
Precision Immunotherapy to Improve Sepsis Outcomes
This randomized trial assesses whether precision immunotherapy tailored to macrophage activation–like syndrome or sepsis-induced immunoparalysis improved organ dysfunction compared with placebo among ...
jamanetwork.com
December 9, 2025 at 11:18 AM
Precision Immunotherapy to Improve Sepsis Outcomes - The ImmunoSep Randomized Clinical Trial
Evangelos J. Giamarellos-Bourboulis, et al.
JAMA, 2025
jamanetwork.com/journals/jam...
Evangelos J. Giamarellos-Bourboulis, et al.
JAMA, 2025
jamanetwork.com/journals/jam...
Chief Investigator, Evangelos Giamarellos-Bourboulis shares the findings from the #ImmunoSep trial and what it means for clinicians at #CCRdownunder
Livestream -> www.criticalcarereviews.com
@jama.com
Livestream -> www.criticalcarereviews.com
@jama.com
December 9, 2025 at 7:13 AM
Chief Investigator, Evangelos Giamarellos-Bourboulis shares the findings from the #ImmunoSep trial and what it means for clinicians at #CCRdownunder
Livestream -> www.criticalcarereviews.com
@jama.com
Livestream -> www.criticalcarereviews.com
@jama.com
IMMUNOSEP trial - JAMA jamanetwork.com/journals/jam... #ccrdownunder 2025
Precision Immunotherapy to Improve Sepsis Outcomes
This randomized trial assesses whether precision immunotherapy tailored to macrophage activation–like syndrome or sepsis-induced immunoparalysis improved organ dysfunction compared with placebo among ...
jamanetwork.com
December 8, 2025 at 10:26 PM
IMMUNOSEP trial - JAMA jamanetwork.com/journals/jam... #ccrdownunder 2025